New oral medication combination for advanced stomach cancer after initial treatment

Plain-English translation of NCT07552402 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing a combination of two oral medications — paclitaxel oral solution plus fruquintinib — to treat advanced stomach cancer that has progressed despite first-line therapy. Researchers want to know if this medication combination is more effective and safer than the standard chemotherapy options that doctors typically choose for patients in this situation.

Patients with advanced stomach cancer that doesn't respond to initial treatment have limited options, and current standard therapies have significant side effects. This trial is exploring whether this medication approach could offer better results with improved tolerability for these patients.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with advanced stomach cancer or esophageal junction cancer that stopped responding to first-line treatment
you have at least one measurable tumor visible on imaging scans
your blood counts, liver, and kidney function are at acceptable levels
you are in good enough overall health to tolerate treatment (performance status 0–1)
you are expected to live at least 12 weeks

You likely don't qualify if…

you have HER2-positive stomach cancer without having received prior anti-HER2 therapy
you have had another type of cancer in the past 3 years
you received chemotherapy or radiation therapy within the past 4 weeks
you have severe side effects from prior cancer treatments that have not resolved
you have severe swallowing problems, uncontrolled nausea, vomiting, or diarrhea that would prevent you from taking oral medication

What participation looks like

If you join this trial, you will be randomly assigned to receive either the new medication combination (taken by mouth on a specific schedule) or your doctor's choice of standard chemotherapy. You will visit the clinic regularly for blood tests, imaging scans, and check-ins to monitor how well the treatment is working and to watch for side effects. The trial involves 150 patients across multiple medical centers, and your participation will help doctors understand whether this new oral approach offers benefits over traditional chemotherapy.

AI-generated summary from trial data · Aug 2, 2026 · Not medical advice

Trial locations(3 sites)

China

The Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang

Baotou Cancer Hospital, Baotou, Inner Mongolia

The Second Hospital of Dalian Medical University, Dalian, Liaoning